Insmed's earnings call highlighted significant clinical and financial achievements, including successful late-stage clinical trials, a strong financial position, and impressive revenue growth. The company is well-prepared for the U.S. launch of brensocatib and has shown promising results from TPIP trials. However, challenges remain in the HS study and potential delays in BiRCh study data release. Overall, the positive developments outweigh the challenges.

Company Guidance -

Q3 2025

During the Insmed Second Quarter 2025 Financial Results Conference Call, the company provided robust guidance for the remainder of the year and beyond. Insmed expects to achieve full-year 2025 sales guidance for ARIKAYCE, driven by consistent year-over-year growth in the U.S., Europe, and Japan, and they anticipate potential expansion into new patient populations pending the successful Phase III ENCORE study. The launch of brensocatib in the U.S. is imminent, with European, U.K., and Japanese launches anticipated in 2026. The company is also advancing TPIP into Phase III trials for PH-ILD in 2025 and PAH in early 2026. Insmed's early-stage portfolio is active, with over 30 preclinical programs, and the company aims to produce 1-2 new INDs annually, underpinned by a solid financial position, with $1.9 billion in cash and marketable securities. This financial strength supports ongoing initiatives, including the U.S. launch of brensocatib and upcoming clinical milestones, which have the potential to significantly increase the company's impact on patients with serious diseases.

Successful Clinical Trials for Late-Stage Assets

Insmed's late-stage assets, ARIKAYCE, brensocatib, and TPIP, have shown positive Phase II or Phase III clinical data, marking a significant achievement for the company.

Strong Financial Position

Insmed reported a solid financial position with approximately $1.9 billion in cash, cash equivalents, and marketable securities, following an equity offering that resulted in $823 million in net proceeds.

Record Revenue Growth for ARIKAYCE

ARIKAYCE recorded double-digit year-over-year revenue growth globally, with notable performances in the U.S., Japan (45% growth), and Europe (48% growth).

Preparedness for Brensocatib U.S. Launch

The company is well-prepared for the anticipated U.S. launch of brensocatib, with a fully built-out sales force ready 10 months ahead of time and extensive payer engagement.

Positive Data from TPIP Trials

TPIP showed promising results in Phase IIb trials for pulmonary arterial hypertension, with a 35% placebo-adjusted reduction in PVR and a significant improvement in 6-minute walk distance.

Strong Pipeline and Research Progress

Insmed is advancing more than 30 preclinical programs across multiple research sites, with significant progress in gene therapy and protein de-immunization platforms.

Insmed (INSM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INSM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	-1.34 / -	-1.27	―	―	―
Aug 07, 2025	2025 (Q2)	-1.29 / -1.70	-1.94	12.37% (+0.24)
May 08, 2025	2025 (Q1)	-1.34 / -1.42	-1.06	-33.96% (-0.36)
Feb 20, 2025	2024 (Q4)	-1.17 / -1.32	-1.28	-3.13% (-0.04)	―
Oct 31, 2024	2024 (Q3)	-1.20 / -1.27	-1.11	-14.41% (-0.16)	―
Aug 08, 2024	2024 (Q2)	-1.24 / -1.94	-1.78	-8.99% (-0.16)	―
May 09, 2024	2024 (Q1)	-1.24 / -1.06	-1.17	9.40% (+0.11)
Feb 22, 2024	2023 (Q4)	-1.15 / -1.28	-1.21	-5.79% (-0.07)
Oct 26, 2023	2023 (Q3)	-1.14 / -1.11	-1.09	-1.83% (-0.02)	―
Aug 03, 2023	2023 (Q2)	-1.13 / -1.78	-0.8	-122.50% (-0.98)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INSM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$111.26	$109.30	-1.76%
May 08, 2025	$68.28	$65.63	-3.88%
Feb 20, 2025	$83.83	$83.61	-0.26%
Oct 31, 2024	$70.30	$67.28	-4.30%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Insmed (INSM) report earnings?

Insmed (INSM) is schdueled to report earning on Oct 23, 2025, TBA (Confirmed).

What is Insmed (INSM) earnings time?

Insmed (INSM) earnings time is at Oct 23, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INSM EPS forecast?

INSM EPS forecast for the fiscal quarter 2025 (Q3) is -1.35.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing